James ND, Sydes MR, Clarke NW, et al : Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE) : survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387: 1163-1177, 2016
Sweeney CJ, Chen YH, Carducci M, et al: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373: 737-746, 2015